Medical Oncologist
HER2-positive breast cancer
Why exactly twelve months of trastuzumab?
Trastuzumab for early HER2-positive breast cancer usually lasts a year, because that is the length that first proved its benefit. Studies later found two years added nothing but more heart effects, and shorter courses gave mixed results. This page explains, in general terms, what the evidence shows.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- Why does trastuzumab treatment last a year?
- Different treatment lengths compared, in general terms
- What your oncologist weighs when deciding length
- How a year of trastuzumab is usually given
- The vocabulary, in plain language
- What the evidence can and cannot settle
- Getting through a long course of treatment
- How the one-year standard came about
- What people assume about the length of trastuzumab
- Common questions about a year of trastuzumab
The short answer
Why does trastuzumab treatment last a year?
A year of trastuzumab became the standard because the large studies that first proved its benefit in early HER2-positive breast cancer used a one-year course. Later studies tested longer and shorter courses. Two years gave no extra benefit and more heart effects. Shorter courses, such as six months, came close to a year in some studies but did not match it for everyone.
Why not longer
Extending treatment to two years did not lower the chance of recurrence further, but it did increase heart side effects. A year offered the best balance.
Why not shorter for everyone
Some studies found six months nearly as effective for many women, with fewer heart effects. Others did not show that shorter courses were as good. A year therefore remains the usual standard.
When a shorter course may be discussed
For women with lower-risk cancers, heart problems during treatment, or significant difficulty with cost or access, an oncologist may discuss a shorter course. This is an individual decision.
This page gives general information only. The length of your treatment is a decision for your oncologist.What studies found
Different treatment lengths compared, in general terms
Length of treatment
What was generally found
About nine weeks
Fewer heart effects, but not shown to match a year
Six months
Close to a year in some studies, not all
One year
The established standard, well proven
Two years
No added benefit, more heart effects
What shapes the decision
What your oncologist weighs when deciding length
For most women a year is recommended. These factors can change that conversation.
Your cancer's risk
Larger cancers and those involving lymph nodes carry more risk, and the full year matters more. Very small cancers may leave more room for discussion.
Your heart
If heart function drops during treatment, pausing or stopping early may be safer. Heart scans guide these decisions.
Most heart changes recover.Response to earlier treatment
If cancer remained at surgery, the plan after surgery usually switches to a different HER2 drug rather than simply shortening the course.
Cost and access
Biosimilars have made a year more affordable in India. Where cost is still a barrier, discuss it openly, since options may exist.
Ask your oncologist
- Is a full year important for me?
- What if my heart scan changes?
- What support is there for cost?
Through the year
How a year of trastuzumab is usually given
Starting with chemotherapy
Trastuzumab usually begins alongside chemotherapy, either before or after surgery.
Continuing every three weeks
After chemotherapy ends, trastuzumab continues on its own every three weeks, as a drip or an injection under the skin.
Heart scans every few months
Regular scans check heart function throughout the year.
Counting treatments, not calendar time
The year is usually measured as a set number of doses. Delays shift the finishing date but the planned total stays the same.
Finishing and follow-up
After the final dose, regular follow-up begins, and hormone therapy continues if your cancer is hormone-sensitive.
Words you will hear
The vocabulary, in plain language
- Trastuzumab
- An antibody that targets the HER2 protein on breast cancer cells.
- Adjuvant
- Treatment after surgery to lower the chance of recurrence.
- Non-inferior
- A study term meaning a treatment was shown to be not meaningfully worse than the standard.
- Biosimilar
- A highly similar version of an antibody medicine, approved after testing against the original.
- Ejection fraction
- A measure of how well the heart pumps, checked during treatment.
- Cardiac monitoring
- Regular heart scans throughout HER2 treatment.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
What the evidence can and cannot settle
The case for a year is strong: it is the length that proved the benefit and has been used for many women over many years. The case against going longer is also clear. The open question is whether some women could safely have less.
Shorter courses are not a simple swap
Studies of shorter courses gave mixed results. Choosing a shorter course means accepting some uncertainty, which may be reasonable in particular situations but is not the default.
Stopping early for heart reasons
If your heart function drops, your oncologist balances the risk to your heart against the benefit of continuing. Many women resume after a pause once the heart recovers.
Newer treatments are changing plans
Pertuzumab, T-DM1 and other drugs have changed HER2 treatment. The year now often includes more than trastuzumab alone.
What this page cannot tell you
It cannot tell you whether a shorter course would be safe for you. Ask your oncologist about your own risk and why they recommend the length they do.
Staying the course
Getting through a long course of treatment
Once chemotherapy ends, visits for trastuzumab alone can feel like an interruption to getting back to normal life. Many women find the later months harder to keep up than they expected.
Keeping appointments
Put every date in a calendar and ask for your next appointment before you leave each visit. If you need to move one, tell the team early so the gap stays short.
Asking about shorter visits
An injection under the skin takes far less time than a drip. Ask whether it is an option, especially if travel or work make long visits difficult.
Speaking up about cost
If cost is making it hard to continue, tell your team before missing doses. There may be biosimilar or support options that make completing the year possible.
Background
How the one-year standard came about
Before trastuzumab, HER2-positive breast cancer had a higher chance of returning than many other types. When large international studies added a year of trastuzumab to chemotherapy, the chance of recurrence fell substantially, and the one-year course was adopted around the world.
Why the length was not tested first
Researchers had to choose a length before they knew the ideal one. A year was a practical choice, and because it worked so well, it became the benchmark that later studies were measured against.
What later research added
Studies comparing shorter and longer courses followed. Together they confirmed that going beyond a year gave nothing extra, while leaving open whether some lower-risk women might safely need less.
Commonly believed
What people assume about the length of trastuzumab
More trastuzumab is always better.
Two years gave no extra benefit over one and caused more heart side effects. A year is the balance the evidence supports.
If I feel fine, I can stop after chemotherapy.
Feeling well does not mean treatment is no longer needed. Continuing trastuzumab after chemotherapy is part of what lowers the chance of recurrence.
Six months is just as good for everyone.
Studies were mixed. For some women a shorter course may be reasonable, but it is not proven to be equal for all, so a year remains the standard.
A missed dose means starting the year again.
A short delay simply shifts the schedule. The planned number of doses stays the same, and your team will rearrange the dates.
Questions we are asked
Common questions about a year of trastuzumab
Does the year include the time on chemotherapy?
Usually yes. The year is counted from the first trastuzumab dose, which often starts alongside chemotherapy. Your team will tell you how many doses make up your course.
Can I ask for a shorter course?
You can discuss it. Your oncologist will explain whether a shorter course might be reasonable for your cancer and what the trade-offs would be.
What if my heart scan changes?
Treatment may be paused and restarted once heart function recovers, which it usually does. Sometimes the course is shortened. Your team will guide you.
Is a biosimilar as good for the full year?
Approved biosimilars are tested to show comparable effect. Many women in India complete the year on a biosimilar. Ask your oncologist about the product planned for you.
Does trastuzumab cause hair loss?
Not on its own. Hair usually regrows during the months of trastuzumab after chemotherapy ends.
Can I travel during the year?
Often yes, if you plan around your dose dates. Tell your team in advance so the schedule can be adjusted if needed.
What happens after the year ends?
Regular follow-up begins, and hormone therapy continues if your cancer is hormone-sensitive. Some women are offered further treatment in particular situations.
Where can I read about my own treatment?
Your oncology team will give you written information about trastuzumab, including side effects and what to report. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Trastuzumab (Herceptin)
- The Lancet — Trastuzumab for six months versus twelve months (PERSEPHONE)
- National Cancer Institute — Breast cancer treatment (PDQ)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.